EQS-News: Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG
|
EQS-News: BRAIN Biotech AG
/ Key word(s): AGM/EGM
Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG ZWINGENBERG, March 18, 2025 – At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all agenda items with a broad majority. Dr. Anna C. Eichhorn and Stephen Catling were re-elected to the Supervisory Board. At the time of voting 63,8 % of the share capital was represented. Dr. Michael Majerus, Chairman of the Supervisory Board, stated: "I am particularly pleased that the Annual General Meeting elected Dr. Anna Eichhorn and Mr. Stephen Catling to the Supervisory Board for an additional term. With their outstanding expertise, both are an integral part of the Supervisory Board's work. Majerus continued: "In the past financial year 2023/24, we were able to successfully prepare and conclude two benchmark transactions together with the Executive Board and thus significantly advance the Company's strategic development." With the publication of the 3M numbers for the financial year 2024/25, the company forecast for the full year a high single-digit to low double-digit percentage increase in sales and an adjusted EBITDA margin of around 10 % in the core segment BRAINBiocatalysts. In his address to shareholders, CEO Adriaan Moelker said: “Last year was in many respects a year of execution for BRAIN Biotech, as we prepared our path to consistently deliver on our goals. We announced the agreement with Royalty Pharma, which can bring BRAIN Biotech up to 129 million Euro in cash. Shortly thereafter, we announced the licensing agreement with Akribion Therapeutics. Taken together, these two transactions represent tremendous value for our shareholders.” The detailed voting results and all other documents relating to the Annual General Meeting are available on the website of BRAIN Biotech AG: https://www.brain-biotech-group.com/en/investors/annual-general-meeting/annual-general-meeting-2025 . +++ BRAIN Biotech Group The BRAIN Biotech Group is a leading company in the research, development and production of specialty enzymes with a focus on the food and life science industries. In addition, the Group develops microbial production organisms and scalable bioprocesses for the economic production of specialty enzymes and other proteins. Customized innovative biological solutions for more sustainable products and processes round off the portfolio. The parent company of the BRAIN Biotech Group is BRAIN Biotech AG. The business activities of the integrated company are divided into the two segments BRAINBiocatalysts (development, production and distribution of specialty enzymes, microorganisms, ingredients) and BRAINBioIncubator (research-intensive development projects, pharmaceuticals). For production, the Group operates fermentation plants in the UK as well as production facilities in continental Europe and the USA. BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 300 people at several locations and generated revenues of EUR 54.6 million in the 2023/24 financial year. Further information can be found at: www.brain-biotech-group.com. Contact Media Dr. Stephanie Konle Contact Investor Relations Martina Schuster The BRAIN Biotech Group on social media and on the internet: BRAIN Biotech Group Web: www.brain-biotech-group.com LinkedIn: https://www.linkedin.com/company/brainbiotech Threads: https://www.threads.net/@brainbiotechag Bluesky: https://bsky.app/profile/brain-biotech-group.com Youtube: https://www.youtube.com/channel/UCS33HJqku674X22UQ8QIsyg Biocatalysts Ltd (Production, Distribution) Website: https://www.biocatalysts.com/ LinkedIn: Biocatalysts Ltd on LinkedIn / BRAIN-Biocatalysts Life Science Solutions on LinkedIn BRAIN Biotech Zwingenberg (Technologies & R&D Services) Website: www.brain-biotech.com LinkedIn: BRAIN Biotech Technologies & Services AnalyticonDiscovery (R&D) Web: https://ac-discovery.com/ LinkedIn: https://www.linkedin.com/company/analyticon-discovery/ Disclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.
18.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | BRAIN Biotech AG |
| Darmstädter Straße 34-36 | |
| 64673 Zwingenberg | |
| Germany | |
| Phone: | +49 (0) 62 51 / 9331-0 |
| Fax: | +49 (0) 62 51 / 9331-11 |
| E-mail: | ir@brain-biotech.com |
| Internet: | www.brain-biotech.com |
| ISIN: | DE0005203947 |
| WKN: | 520394 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2102590 |
| End of News | EQS News Service |
|
|
2102590 18.03.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 38,56 | 38,23 | 38,39 | 45,51 | 55,34 | 54,63 | 62,50 | |
| EBITDA1,2 | -2,50 | -3,88 | -2,53 | -1,31 | -0,83 | -4,03 | -1,00 | |
| EBITDA-Margin3 | -6,48 | -10,15 | -6,59 | -2,88 | -1,50 | -7,38 | -1,60 | |
| EBIT1,4 | -7,20 | -8,23 | -6,55 | -5,65 | -5,48 | -8,85 | -3,50 | |
| EBIT-Margin5 | -18,67 | -21,53 | -17,06 | -12,42 | -9,90 | -16,20 | -5,60 | |
| Net Profit (Loss)1 | -11,12 | -9,02 | -4,68 | -6,34 | -8,11 | -11,10 | -5,80 | |
| Net-Margin6 | -28,84 | -23,59 | -12,19 | -13,93 | -14,66 | -20,32 | -9,28 | |
| Cashflow1,7 | -3,38 | -4,77 | -3,10 | -1,49 | -4,22 | -3,58 | -1,15 | |
| Earnings per share8 | -0,61 | -0,52 | -0,25 | -0,30 | -0,38 | -0,51 | -0,26 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Baker Tilly
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| BRAIN Biotech | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 520394 | DE0005203947 | AG | 51,56 Mio € | 09.02.2016 | Halten | 8FXCPJH6+57 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 18,15 | 0,00 | 0,00 | -4,89 | 4,09 | -14,39 | 0,94 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 18.03.2025 | 26.02.2025 | 28.05.2025 | 28.08.2025 | 15.01.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -11,78% | -8,56% | -33,52% | -23,87% | -73,78% |
